The Captopril-Induced Eruption
- 1 August 1980
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 116 (8), 902-905
- https://doi.org/10.1001/archderm.1980.01640320052013
Abstract
• Captopril, an orally active dipeptidylcarboxypeptidase inhibitor, is a promising new antihypertensive agent. Cutaneous reactions are the most common side effects of this therapy. The data from 15 previous cases and seven new ones are reviewed. The cutaneous eruptions appear to be pharmacologic in nature, occurring mostly at higher dosage schedules and resolving at lower dosage levels. Historical data, the results of skin tests, and the known pharmacology of captopril suggest that these captopril-induced eruptions may be the result of potentiation of kinin-mediated cutaneous reactions. (Arch Dermatol 116:902-905, 1980)This publication has 6 references indexed in Scilit:
- Treatment of chronic urticaria with a proteinase (kallikrein) inhibitorBritish Journal of Dermatology, 2006
- Converting enzyme inhibition with an orally active compound in hypertensive man.Hypertension, 1978
- Accentuated Vascular and Endocrine Response to Sq 20881 in HypertensionNew England Journal of Medicine, 1977
- MECHANISMS OF THE FLARE REACTION IN HUMAN SKINJournal of Investigative Dermatology, 1977
- Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive AgentsScience, 1977
- Molecular Inflammation Of The SkinJournal of Investigative Dermatology, 1971